BR112012002349A2 - composto,e, uso do mesmo - Google Patents
composto,e, uso do mesmoInfo
- Publication number
- BR112012002349A2 BR112012002349A2 BR112012002349A BR112012002349A BR112012002349A2 BR 112012002349 A2 BR112012002349 A2 BR 112012002349A2 BR 112012002349 A BR112012002349 A BR 112012002349A BR 112012002349 A BR112012002349 A BR 112012002349A BR 112012002349 A2 BR112012002349 A2 BR 112012002349A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23213209P | 2009-08-07 | 2009-08-07 | |
| PCT/US2010/044703 WO2011017611A1 (en) | 2009-08-07 | 2010-08-06 | Lipidated oxoadenine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012002349A2 true BR112012002349A2 (pt) | 2015-10-13 |
Family
ID=43544685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012002349A BR112012002349A2 (pt) | 2009-08-07 | 2010-08-06 | composto,e, uso do mesmo |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9044481B2 (pt) |
| EP (2) | EP2461690A4 (pt) |
| JP (1) | JP5759992B2 (pt) |
| KR (1) | KR20120055623A (pt) |
| CN (1) | CN102469790B (pt) |
| AU (1) | AU2010279299B2 (pt) |
| BR (1) | BR112012002349A2 (pt) |
| CA (1) | CA2768195A1 (pt) |
| EA (1) | EA023536B1 (pt) |
| ES (1) | ES2732999T3 (pt) |
| MX (1) | MX2012001524A (pt) |
| SG (1) | SG178237A1 (pt) |
| TR (1) | TR201909600T4 (pt) |
| WO (1) | WO2011017611A1 (pt) |
| ZA (1) | ZA201200646B (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
| CA2733743A1 (en) * | 2008-08-11 | 2010-02-18 | Glaxosmithkline Llc | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| EA019204B1 (ru) * | 2008-08-11 | 2014-01-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные аденина и их применение в терапии |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| US8962652B2 (en) | 2009-10-22 | 2015-02-24 | Gilead Sciences, Inc. | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
| WO2011098451A1 (en) * | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
| WO2011134668A1 (en) | 2010-04-30 | 2011-11-03 | Telormedix Sa | Phospholipid drug analogs |
| AU2011247359A1 (en) * | 2010-04-30 | 2012-11-15 | Telormedix Sa | Methods for inducing an immune response |
| US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
| CA2841361A1 (en) | 2011-07-22 | 2013-01-31 | Glaxosmithkline Llc | Composition for the treatment of allergic diseases and inflammatory conditions |
| EP2674170B1 (en) * | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
| JP6196674B2 (ja) | 2012-08-24 | 2017-09-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | ピラゾロピリミジン化合物 |
| ES2625023T3 (es) | 2012-11-20 | 2017-07-18 | Glaxosmithkline Llc | Compuestos novedosos |
| AU2013348217B2 (en) | 2012-11-20 | 2016-10-06 | Glaxosmithkline Llc | Novel compounds |
| UA114645C2 (uk) | 2012-11-20 | 2017-07-10 | Ґлаксосмітклайн Ллк | Піролопіримідини як індуктори інтерферону людини |
| US9295732B2 (en) | 2013-02-22 | 2016-03-29 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
| WO2015036044A1 (en) * | 2013-09-13 | 2015-03-19 | Telormedix Sa | Cationic lipid vehicles for delivery of tlr7 agonists for specific targeting of human cd14+ monocytes in whole blood |
| DK3134402T3 (da) | 2014-04-22 | 2020-07-20 | Hoffmann La Roche | 4-amino-imidazoquinolinforbindelser |
| ES2917887T3 (es) | 2014-11-13 | 2022-07-12 | Glaxosmithkline Biologicals Sa | Derivados de adenina que son útiles en el tratamiento de enfermedades alérgicas u otras afecciones inflamatorias |
| ES2712488T3 (es) | 2015-03-06 | 2019-05-13 | Hoffmann La Roche | Compuestos de benzacepina-dicarboxamida |
| WO2016142880A1 (en) * | 2015-03-10 | 2016-09-15 | Glaxosmithkline Biologicals Sa | Compositions and uses |
| EP3350168B1 (en) | 2015-09-17 | 2019-12-18 | H. Hoffnabb-La Roche Ag | Sulfinylphenyl or sulfonimidoylphenyl benzazepines |
| WO2017056494A1 (en) | 2015-09-29 | 2017-04-06 | Sumitomo Dainippon Pharma Co., Ltd. | Adenine conjugate compounds and their use as vaccine adjuvants |
| EP3868741B1 (en) | 2015-10-07 | 2023-08-30 | Sumitomo Pharma Co., Ltd. | Composition comprising a pyrimidine compound and a pathogen derived antigen |
| CN108368138A (zh) | 2015-12-14 | 2018-08-03 | 葛兰素史密丝克莱恩生物有限公司 | 咪唑并喹啉类和氧代腺嘌呤类的磷酸脂化 |
| JP7022702B2 (ja) | 2016-05-23 | 2022-02-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
| EP3464245B1 (en) | 2016-05-23 | 2020-10-14 | H. Hoffnabb-La Roche Ag | Benzazepine dicarboxamide compounds with tertiary amide function |
| EP3468963B1 (en) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl benzazepine carboxamide compounds |
| US20210371440A1 (en) | 2018-04-13 | 2021-12-02 | Glaxosmithkline Biologicals Sa | Tlr7 and / or tlr8 agonists |
| UA128528C2 (uk) | 2018-07-03 | 2024-08-07 | Джянгсу Хенгруй Медісін Ко., Лтд. | Похідна піридопіримідину, спосіб її отримання та її медичне застосування |
| SG11202100706UA (en) | 2018-07-23 | 2021-03-30 | Japan As Represented By Director General Of Nat Institute Of Infectious Diseases | Composition containing influenza vaccine |
| CA3138461A1 (en) * | 2019-05-23 | 2020-11-26 | Helene Bazin-Lee | Vaccine adjuvants based on tlr receptor ligands |
| WO2020255038A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| AU2020416484A1 (en) | 2020-01-02 | 2022-08-25 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of pyridopyrimidine derivative and preparation method thereof |
| KR102549083B1 (ko) | 2021-02-01 | 2023-06-29 | 주식회사 에이티솔루션 | 레이다 전자 표적 발생 장치에서 발생되는 표적의 거리를 최소화하는 전파 지연 장치 및 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3042540B2 (ja) * | 1990-08-20 | 2000-05-15 | ミヨシ油脂株式会社 | ８―ヒドロキシアデノシン―５′―リン酸を含むアデノシンモノホスフェート系三量体、その製造方法及びその化合物からなる蛋白質合成阻害剤 |
| JPH093091A (ja) * | 1995-06-21 | 1997-01-07 | Rikagaku Kenkyusho | ヌクレオシド誘導体物質、その製造法及び抗腫瘍剤 |
| EP0882727B9 (en) | 1996-07-03 | 2005-06-15 | Sumitomo Pharmaceuticals Company, Limited | Novel purine derivatives |
| EP1474432A1 (en) | 2002-02-04 | 2004-11-10 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| WO2007034881A1 (ja) * | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| SI2038290T1 (sl) | 2006-07-07 | 2014-01-31 | Gilead Sciences, Inc. | Modulatorji Tollu podobnega receptorja 7 |
| US8067413B2 (en) * | 2007-03-19 | 2011-11-29 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7 ) modulators |
| EP2326646B1 (en) * | 2008-08-11 | 2013-07-31 | GlaxoSmithKline LLC | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| CA2733743A1 (en) * | 2008-08-11 | 2010-02-18 | Glaxosmithkline Llc | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
-
2010
- 2010-08-06 TR TR2019/09600T patent/TR201909600T4/tr unknown
- 2010-08-06 CN CN201080034927.7A patent/CN102469790B/zh not_active Expired - Fee Related
- 2010-08-06 BR BR112012002349A patent/BR112012002349A2/pt not_active Application Discontinuation
- 2010-08-06 SG SG2012007522A patent/SG178237A1/en unknown
- 2010-08-06 KR KR1020127005993A patent/KR20120055623A/ko not_active Application Discontinuation
- 2010-08-06 CA CA2768195A patent/CA2768195A1/en not_active Abandoned
- 2010-08-06 ES ES16190246T patent/ES2732999T3/es active Active
- 2010-08-06 US US13/389,307 patent/US9044481B2/en active Active
- 2010-08-06 AU AU2010279299A patent/AU2010279299B2/en not_active Ceased
- 2010-08-06 WO PCT/US2010/044703 patent/WO2011017611A1/en active Application Filing
- 2010-08-06 MX MX2012001524A patent/MX2012001524A/es active IP Right Grant
- 2010-08-06 EA EA201290036A patent/EA023536B1/ru not_active IP Right Cessation
- 2010-08-06 EP EP20100807229 patent/EP2461690A4/en not_active Withdrawn
- 2010-08-06 JP JP2012523976A patent/JP5759992B2/ja not_active Expired - Fee Related
- 2010-08-06 EP EP16190246.5A patent/EP3199159B1/en active Active
-
2012
- 2012-01-25 ZA ZA2012/00646A patent/ZA201200646B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2768195A1 (en) | 2011-02-10 |
| ES2732999T3 (es) | 2019-11-27 |
| AU2010279299A1 (en) | 2012-03-29 |
| CN102469790A (zh) | 2012-05-23 |
| EP3199159B1 (en) | 2019-04-10 |
| EP2461690A4 (en) | 2013-03-27 |
| WO2011017611A1 (en) | 2011-02-10 |
| JP5759992B2 (ja) | 2015-08-05 |
| EP2461690A1 (en) | 2012-06-13 |
| EA023536B1 (ru) | 2016-06-30 |
| US9044481B2 (en) | 2015-06-02 |
| CN102469790B (zh) | 2014-12-03 |
| EP3199159A1 (en) | 2017-08-02 |
| JP2013501730A (ja) | 2013-01-17 |
| MX2012001524A (es) | 2012-02-29 |
| TR201909600T4 (tr) | 2019-07-22 |
| SG178237A1 (en) | 2012-03-29 |
| US20120135963A1 (en) | 2012-05-31 |
| ZA201200646B (en) | 2013-06-26 |
| EA201290036A1 (ru) | 2012-12-28 |
| KR20120055623A (ko) | 2012-05-31 |
| AU2010279299B2 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012002349A2 (pt) | composto,e, uso do mesmo | |
| BRPI1012533A2 (pt) | composto de piradazinona e uso do mesmo | |
| BRPI1012861A2 (pt) | catalisador, e, uso do catalisador | |
| BRPI1007494A2 (pt) | composto e uso do mesmo | |
| BRPI0821668A2 (pt) | Uso | |
| NO2021006I1 (no) | Quofenix, delafloksacin | |
| BRPI0909770A2 (pt) | Vacina, e, kit | |
| BRPI0915134A2 (pt) | composto, e, uso de um composto | |
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| BRPI0821276A2 (pt) | Produto, e, uso do produto | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| BR112012031232A2 (pt) | método, dispositivo e uso | |
| BRPI0907453A2 (pt) | Compostos, uso e preparação dos mesmos | |
| FI20086253A0 (fi) | Sieniendoglukanaasit, niiden valmistus ja käyttö | |
| FI20086250A0 (fi) | Sieniendoglukanaasit, niiden valmistus ja käyttö | |
| SMT201500218B (it) | Composti aril-fenil-solfonammido-cicloalchile e loro uso | |
| DK2125048T3 (da) | Præparat | |
| BRPI1006996A2 (pt) | composição, método e uso | |
| BRPI1011036A2 (pt) | uso | |
| BRPI0818641A2 (pt) | Rótulo, e, uso do rótulo | |
| CO6781486A2 (es) | Compuestos y su uso | |
| BRPI1015091A2 (pt) | novo uso | |
| BRPI1013597A2 (pt) | seringa para uso único | |
| BRPI0909840A2 (pt) | Uso de 4-tio-2-deoxinucleosídios | |
| BR112013012175A2 (pt) | combinação, coadministração, uso e método |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |